ISSN: 1859 - 2872
Clinico-radiological features and treatment of brain metastasis from papillary thyroid carcinoma: A case series from 2016 - 2021 at 108 Military Central Hospital
Main Article Content
Abstract
The brain is an unusual site for distant metastases of papillary thyroid carcinoma (PTC), with a frequency of about 0.15% - 1.3%. The metastases from PTC often occur in cervical lymph nodes, lungs, bones,... leading to a poor prognosis. However, few of those patients have initial neurological symptoms suggestive of metastatic brain damage. Conventional diagnostic imagings including MRI and I-131 whole-body scan, SPECT/CT and 18F-FDG PET/CT create favorable conditions for early brain metastasis detection. There are no standardized therapy strategies for metastatic brain lesions from PTC but mainly rely on brain metastatic cancer treatment guidelines and clinical experiences. The paper presents three brain metastasis patients from papillary thyroid carcinoma detected in Nuclear Medicine Department, 108 Military Central Hospital in 5 years from 2016-2021. We also discusses clinical and radiological features, diagnostic and treatment approaches in those rare patients.
Article Details
References
2. Gomes-Lima CJ et al (2019) Brain metastases from differentiated thyroid carcinoma: prevalence, current therapies, and outcomes. Journal of the Endocrine Society 3(2): 359-371.
3. Hardesty DA and Nakaji P (2016) The current and future treatment of brain metastases. Frontiers in surgery 3: 30.
4. Haugen BR et al (2017) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: What is new and what has changed?. Cancer 123(3): 372-381.
5. Linskey ME et al (2010) The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. Journal of neuro-oncology 96(1): 45-68.
6. Chiu AC, Delpassand ES, and Sherman SI (1997) Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82(11): 3637-3642.
7. Gaspar L et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4): 745-751.
8. Kocher M et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 29(2): 134-141.
9. McConahey WM et al (1986) Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61(12): 978-996.
10. Parker LN et al (1986) Recurrence of papillary thyroid carcinoma presenting as a focal neurologic deficit. Arch Intern Med 146(10): 1985-1987.
11. Soffietti R, Trevisan E, and Rudà R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24(6): 679-686.
12. Vecht CJ et al (1994) Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: A randomized study of doses of 4, 8, and 16mg per day. Neurology 44(4): 675-680.
Article Sidebar
